CA-VEEVA-SYSTEMS
4.2.2021 13:05:06 CET | Business Wire | Press release
Veeva Systems (NYSE: VEEV) today announced that 6 out of the top 7 global CROs have joined the Veeva Vault CDMS partner program. Accelerating clinical research is a top priority in the life sciences industry. All of the top 7 CROs, except IQVIA, which has decided not to join the program at this time, are now able to leverage Veeva Vault CDMS capabilities to modernize clinical data management and build high-quality studies faster.
The growth of Veeva’s CRO partner program is enabling an industrywide shift to a modern clinical data management platform that better meets the needs of today’s clinical trials. Now 6 out of the top 7 global CROs have access to the support and training needed to build and execute studies with Veeva. As the need to run faster and more efficient trials grows, CROs are using Veeva's advanced technology to help sponsors improve trial performance.
“Veeva is enabling CROs to work more effectively with sponsors during the build process to accelerate trial starts,” said Henry Levy, general manager of Veeva Vault CDMS. “Our CRO partners are leading the way towards faster, more collaborative studies and continued excellence in trials.”
Vault CDMS is a modern cloud application suite that combines electronic data capture (EDC) , coding , data cleaning , and reporting . Customers are able to build study databases in six weeks or less and make mid-study amendments with zero downtime, freeing customers to run the trials they want without technology limitations.
Emerging biotechs are benefitting from the growing number of CROs adopting Vault CDMS. The access to a modern clinical data management solution provides them with the speed and nimbleness to accelerate clinical research.
The six global CROs joining Veeva’s partner program are Covance, ICON, Parexel, PPD, PRA Health Sciences, and Syneos Health. For CROs interested in learning more about the program, contact info@veeva.com .
What CROs are saying about Veeva Vault CDMS:
“ICON supports clients to accelerate clinical development and advance healthcare through applied technology,” said Lalit Pai, senior vice president, biometrics at ICON . “Veeva’s innovative clinical data management platform is enabling us to manage and deliver seamless integration for our clients and meet rigorous, global quality standards.”
“Veeva has an outstanding reputation in the industry and within our organization, as we have widely adopted many of its other platforms,” said Simon Fleming, vice president, data management at Parexel . “Veeva Vault CDMS provides us with an exciting opportunity to further build on our relationship and provide customers with more choice and flexibility.”
“PPD continues to expand our technology offerings focused on providing accelerated decision-making for our customers,” said Rob Petrie, senior vice president and chief technology officer at PPD . “The implementation of Veeva Vault CDMS provides PPD the flexibility to continue to provide innovative technologies, furthering PPD’s mission of bending the time and cost curve of drug development and enabling our clinical research teams to continue to raise the bar by providing the highest level of service and quality to our customers.”
“Veeva Vault CDMS is a valuable addition to our existing biometrics technology offerings and will provide our clients and partners with a greater choice,” said Michael Goedde, vice president, global data operations at PRA Health Sciences . “Veeva has been a respected and valued partner of ours for many years, and now we will be able to further enhance our clinical data management services as the drug development industry evolves.”
“At Syneos Health, our focus has always been on running clinical trials in the most efficient and integrated manner, and with the highest quality processes and procedures,” said Paul Colvin, president, clinical solutions at Syneos Health . “Our long-standing relationship with Veeva, combined with Veeva Vault CDMS, will allow us to accelerate our operational capabilities and work more collaboratively with our clients.”
Additional Information
For more on Veeva Vault CDMS, visit: veeva.com/CDMS
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 950 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu .
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended October 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov . Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
® 2021 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other registered and unregistered trademarks.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210204005394/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Secures First Heart Health Claim for Soy Protein in Australia and New Zealand31.3.2026 16:00:00 CEST | Press release
Regulatory milestone opens heart health growth opportunities for food and beverage manufacturers IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients and health & biosciences announced today that a new heart health claim for isolated soy protein has been accepted by the Food Standards Australia New Zealand (FSANZ). The approval enables food and beverage manufacturers in Australia and New Zealand to link soy protein consumption with healthy blood cholesterol levels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330523416/en/ First heart health claim approved for soy protein in Australia and New Zealand. “For decades, IFF has invested in the science behind soy protein and its role in supporting cardiovascular health,” said Tony Andrew, vice president of protein solutions for IFF Food Ingredients. “This approved claim validates years of rigorous research and collaboration. With our deep expertise in ing
Sub-Q Bionics Closes $1.5M Pre-Seed Round to Advance Next-Generation Solution for Lymphedema Care31.3.2026 15:26:00 CEST | Press release
Sub-Q Bionics, a medical device company developing next-generation solutions to improve care for patients living with lymphedema, today announced the successful close of its $1.5 million pre-seed funding round. The round includes investment from Mayo Clinic and Yeda, the technology transfer company of the Weizmann Institute of Science, as well as several private investors. The Israel Innovation Authority also provided matching funds. The funding will enable Sub-Q Bionics to continue to develop its novel bionic lymph node technology designed to transform how lymphedema is managed, based on scientific innovations from the Weizmann Institute and Shamir Medical Center. The system aims to provide a solution to manage fluid with a subcutaneous implant that will allow patients freedom of movement, automatic fluid management and reduction of symptoms such as pain and swelling. Lymphedema affects millions of patients worldwide, especially breast cancer survivors, and remains significantly under
HTEC Achieves SOC 2 Type II Attestation, Reinforcing Commitment to Client Trust31.3.2026 15:25:00 CEST | Press release
HTECtoday announced that it has successfully achieved a SOC 2 Type II attestation, audited by Deloitte, demonstrating the company’s commitment to maintaining high standards in security, availability, and confidentiality. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331132225/en/ HTEC today announced that it has successfully achieved a SOC 2 Type II attestation, audited by Deloitte, demonstrating the company’s commitment to maintaining high standards in security, availability, and confidentiality. For clients, this means working with a technology partner whose practices are standardized, consistently executed, and independently verified over time. It reflects a level of operational maturity where security, reliability, and data protection are built into every engagement. Achieving this standard required coordinated effort across the entire organization. Compliance, engineering, delivery, security, IT, legal, and people t
Impartner Redefines Partner Marketing Automation with Full Automation, AdTech and AI to Drive Measurable Revenue31.3.2026 15:00:00 CEST | Press release
New automation and AI capabilities connect partner campaigns and engagement directly to pipeline and revenue outcomes. Impartner, the world’s leading partner revenue orchestration platform, today announced a major advancement that unifies partner marketing automation within the platform, powered by full automation, AdTech and AI to turn partner marketing into measurable revenue. As partner ecosystems expand across regions, marketplaces and multi-tier models, marketing execution has often remained fragmented. Impartner eliminates those gaps by unifying recruitment, enablement, campaign automation and performance tracking within a single operational system, making partner demand generation and marketing fully operational, measurable, and scalable across all partner interactions. “What makes partner marketing successful is not content distribution, it’s execution, scale and measurable pipeline and revenue,” said Emile van de Klok, Senior Director of Channel Marketing Solutions at Impartne
Boomi Named a Leader in IDC MarketScape for Worldwide API Management 202631.3.2026 15:00:00 CEST | Press release
Boomi™, the data activation company, today announced it has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment, which evaluates vendors based on their capabilities and strategies for delivering API management solutions (APIM) in an increasingly AI-driven, hybrid enterprise landscape. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331354139/en/ Boomi Named a Leader in IDC MarketScape for Worldwide API Management 2026 As enterprises accelerate adoption of agentic AI and hybrid architectures, the need to govern and scale APIs across increasingly complex environments has become a strategic priority. APIs are central to enabling secure, reusable, and agent-ready access to applications and data. Boomi’s API management solution, with an enterprise-grade gateway and advanced federation capabilities, enables organizations to design, secure, and manage APIs seamlessly across distributed runt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom